Teva Pharmaceutical Industries annual total debt
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Total Debt Growth & History (TEVA)
Teva Pharmaceutical Industries's total debt was $2.25B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.25B | $58.0M | +2.65% |
| 2024 | 2024-12-31 | $2.19B | $66.0M | +3.11% |
| 2023 | 2023-12-31 | $2.12B | −$452.0M | −17.57% |
| 2022 | 2022-12-31 | $2.57B | $597.0M | +30.21% |
| 2021 | 2021-12-31 | $1.98B | −$1.83B | −48.05% |
| 2020 | 2020-12-31 | $3.80B | $877.0M | +29.96% |
| 2019 | 2019-12-31 | $2.93B | $711.0M | +32.08% |
| 2018 | 2018-12-31 | $2.22B | −$26.61B | −92.31% |
| 2017 | 2017-12-31 | $28.83B | −$3.71B | −11.40% |
| 2016 | 2016-12-31 | $32.54B | — | — |
| 2013 | 2013-12-31 | $11.20B | −$2.94B | −20.79% |
| 2012 | 2012-12-31 | $14.14B | $2.75B | +24.13% |
| 2011 | 2011-12-31 | $11.39B | $9.95B | +688.51% |
| 2010 | 2010-12-31 | $1.45B | −$31.0M | −2.10% |
| 2009 | 2009-12-31 | $1.48B | −$3.25B | −68.78% |
| 2008 | 2008-12-31 | $4.73B | — | — |
Teva Pharmaceutical Industries quarterly total debt
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.78B | $4.02B | +529.21% |
| Q1 2026 | 2026-03-31 | $2.89B | $2.18B | +307.90% |
| Q4 2025 | 2025-12-31 | $2.25B | $58.0M | +2.65% |
| Q3 2025 | 2025-09-30 | $307.0M | −$2.57B | −89.32% |
| Q2 2025 | 2025-06-30 | $760.0M | −$1.61B | −68.00% |
| Q1 2025 | 2025-03-31 | $709.0M | −$2.65B | −78.86% |
| Q4 2024 | 2024-12-31 | $2.19B | $66.0M | +3.11% |
| Q3 2024 | 2024-09-30 | $2.88B | $1.07B | +59.46% |
| Q2 2024 | 2024-06-30 | $2.38B | $57.0M | +2.46% |
| Q1 2024 | 2024-03-31 | $3.35B | $1.99B | +145.18% |
| Q4 2023 | 2023-12-31 | $2.12B | −$452.0M | −17.57% |
| Q3 2023 | 2023-09-30 | $1.80B | −$1.32B | −42.27% |
| Q2 2023 | 2023-06-30 | $2.32B | $228.0M | +10.91% |
| Q1 2023 | 2023-03-31 | $1.37B | −$1.10B | −44.62% |
| Q4 2022 | 2022-12-31 | $2.57B | $597.0M | +30.21% |
| Q3 2022 | 2022-09-30 | $3.12B | −$11.0M | −0.35% |
| Q2 2022 | 2022-06-30 | $2.09B | −$1.88B | −47.41% |
| Q1 2022 | 2022-03-31 | $2.47B | −$668.0M | −21.29% |
| Q4 2021 | 2021-12-31 | $1.98B | −$1.83B | −48.05% |
| Q3 2021 | 2021-09-30 | $3.13B | $556.0M | +21.57% |
| Q2 2021 | 2021-06-30 | $3.97B | $1.91B | +92.63% |
| Q1 2021 | 2021-03-31 | $3.14B | $1.10B | +53.75% |
| Q4 2020 | 2020-12-31 | $3.80B | $877.0M | +29.96% |
| Q3 2020 | 2020-09-30 | $2.58B | −$1.09B | −29.74% |
| Q2 2020 | 2020-06-30 | $2.06B | −$1.28B | −38.31% |
| Q1 2020 | 2020-03-31 | $2.04B | −$1.31B | −39.15% |
| Q4 2019 | 2019-12-31 | $2.93B | $711.0M | +32.08% |
| Q3 2019 | 2019-09-30 | $3.67B | $996.0M | +37.26% |
| Q2 2019 | 2019-06-30 | $3.34B | $2.07B | +162.89% |
| Q1 2019 | 2019-03-31 | $3.35B | $2.05B | +157.60% |
| Q4 2018 | 2018-12-31 | $2.22B | −$26.61B | −92.31% |
| Q3 2018 | 2018-09-30 | $2.67B | −$29.30B | −91.64% |
| Q2 2018 | 2018-06-30 | $1.27B | −$32.65B | −96.25% |
| Q1 2018 | 2018-03-31 | $1.30B | −$31.54B | −96.04% |
| Q4 2017 | 2017-12-31 | $28.83B | −$3.71B | −11.40% |
| Q3 2017 | 2017-09-30 | $31.97B | −$1.21B | −3.63% |
| Q2 2017 | 2017-06-30 | $33.92B | $25.89B | +322.11% |
| Q1 2017 | 2017-03-31 | $32.84B | $24.20B | +279.90% |
| Q4 2016 | 2016-12-31 | $32.54B | $24.11B | +285.85% |
| Q3 2016 | 2016-09-30 | $33.18B | $31.03B | +1444.65% |
| Q2 2016 | 2016-06-30 | $8.04B | $5.01B | +165.92% |
| Q1 2016 | 2016-03-31 | $8.64B | $7.02B | +431.67% |
| As of Dec 31, 2015 | 2015-12-31 | $8.43B | −$179.0M | −2.08% |
| As of Sep 30, 2015 | 2015-09-30 | $2.15B | $316.0M | +17.25% |
| As of Jun 30, 2015 | 2015-06-30 | $3.02B | $974.0M | +47.56% |
| As of Mar 31, 2015 | 2015-03-31 | $1.63B | $74.0M | +4.77% |
| As of Dec 31, 2014 | 2014-12-31 | $8.61B | −$2.59B | −23.13% |
| Q3 2014 | 2014-09-30 | $1.83B | −$704.0M | −27.76% |
| Q2 2014 | 2014-06-30 | $2.05B | −$486.0M | −19.18% |
| Q1 2014 | 2014-03-31 | $1.55B | −$1.17B | −42.94% |
| Q4 2013 | 2013-12-31 | $11.20B | −$2.94B | −20.79% |
| Q3 2013 | 2013-09-30 | $2.54B | $1.97B | +344.13% |
| Q2 2013 | 2013-06-30 | $2.53B | $1.65B | +185.04% |
| Q1 2013 | 2013-03-31 | $2.72B | −$1.11B | −29.06% |
| Q4 2012 | 2012-12-31 | $14.14B | $2.75B | +24.13% |
| Q3 2012 | 2012-09-30 | $571.0M | −$2.71B | −82.61% |
| Q2 2012 | 2012-06-30 | $889.0M | −$1.04B | −53.87% |
| Q1 2012 | 2012-03-31 | $3.83B | $2.49B | +185.91% |
| Q4 2011 | 2011-12-31 | $11.39B | $9.95B | +688.51% |
| Q3 2011 | 2011-09-30 | $3.28B | $2.19B | +201.19% |
| Q2 2011 | 2011-06-30 | $1.93B | −$40.0M | −2.03% |
| Q1 2011 | 2011-03-31 | $1.34B | −$680.0M | −33.65% |
| Q4 2010 | 2010-12-31 | $1.45B | −$31.0M | −2.10% |
| Q3 2010 | 2010-09-30 | $1.09B | −$1.22B | −52.77% |
| Q2 2010 | 2010-06-30 | $1.97B | −$922.0M | −31.91% |
| Q1 2010 | 2010-03-31 | $2.02B | −$2.54B | −55.72% |
| Q4 2009 | 2009-12-31 | $1.48B | −$3.25B | −68.78% |
| Q3 2009 | 2009-09-30 | $2.31B | — | — |
| Q2 2009 | 2009-06-30 | $2.89B | — | — |
| Q1 2009 | 2009-03-31 | $4.56B | — | — |
| Q4 2008 | 2008-12-31 | $4.73B | — | — |
Teva Pharmaceutical Industries total debt trends
Over the last five fiscal years, Teva Pharmaceutical Industries's total debt decreased from $3.80B to $2.25B, a change of −$1.56B. The latest reported quarter, Q2 2026, shows $4.78B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗